KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Total Debt (2016 - 2025)

Historic Total Debt for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $202.8 million.

  • West Pharmaceutical Services' Total Debt rose 9.87% to $202.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $202.8 million, marking a year-over-year increase of 9.87%. This contributed to the annual value of $202.8 million for FY2025, which is 9.87% up from last year.
  • According to the latest figures from Q4 2025, West Pharmaceutical Services' Total Debt is $202.8 million, which was up 9.87% from $202.7 million recorded in Q3 2025.
  • West Pharmaceutical Services' Total Debt's 5-year high stood at $254.6 million during Q1 2021, with a 5-year trough of $72.8 million in Q4 2023.
  • In the last 5 years, West Pharmaceutical Services' Total Debt had a median value of $204.8 million in 2022 and averaged $192.9 million.
  • Over the last 5 years, West Pharmaceutical Services' Total Debt had its largest YoY gain of 17829.67% in 2024, and its largest YoY loss of 6505.04% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Total Debt (Quarter) stood at $253.0 million in 2021, then fell by 18.3% to $206.7 million in 2022, then tumbled by 64.78% to $72.8 million in 2023, then soared by 178.3% to $202.6 million in 2024, then grew by 0.1% to $202.8 million in 2025.
  • Its last three reported values are $202.8 million in Q4 2025, $202.7 million for Q3 2025, and $202.6 million during Q2 2025.